Clinical trials: GLP - 1
Obesity Prevention, Sarcopenia in Elderly
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor…
- Conditions
- Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1
- Trial name
- NCT06811324
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Nutrition Intake, Nutrition Status
A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs
This study is a triple-blind, placebo-controlled, randomized controlled trial of 120 adults that will evaluate the impact of a novel nutritional supplement on improving nutrient gaps and changing nutrient status and the gut…
- Conditions
- Nutrition Intake, Nutrition Status, Gastrointestinal Microbiome, GLP-1
- Trial name
- NCT07437911
- Testing
- AG1 - Nutritional Supplement
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Athletic Greens International
To Investigate the Physiological Effect of GLP-1 on the Skeleton, Healthy Volunteer
SHORT-term Effects of GLucagon-like Peptide One on BonE
Bone is a dynamic organ that is remodelled throughout life by a coupled process of resorption and formation of bone tissue, which are highly energy-demanding processes.
- Trial name
- SHORT-GLOBE (NCT06722560)
- Testing
- GLP-1 hormone
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Obesity, Depression
GLP-1 Medicines and Mental Health Changes
Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment…
- Conditions
- Obesity, Depression, GLP-1
- Trial name
- NCT07368855
- Testing
- GLP-1
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of California, San Diego
Gastrointestinal Symptoms, Weight Loss
A Trial to Assess Gastrointestinal Responses to Dietary Fibers in Adults Using Weight Loss Medications
The objective of this study is to assess self-reported gastrointestinal (GI) responses to three snack bars containing fiber/fiber blends vs. a control snack bar for 7 days each in adults using GLP-1 agonists.
- Conditions
- Gastrointestinal Symptoms, Weight Loss, GLP-1
- Trial name
- NCT07012317
- Testing
- High Fiber Bar with Inulin, High Fiber bar with Fiber Blend, High Fiber Bar with Resistant Starch type 4
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research
Rectal Cancer Patients, Obesity &Amp; Overweight
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer
The goal of this clinical trial is to see if adding a weight loss medication (GLP-1 receptor drug) to patients with an increased BMI receiving treatment for rectal cancer prior to surgery (total neoadjuvant chemoradiotherapy)…
- Conditions
- Rectal Cancer Patients, Obesity &Amp; Overweight, Locally Advanced Rectal Cancer (LARC), Total Neoadjuvant Therapy
- Trial name
- NCT07314528
- Testing
- GLP-1 receptor agonist, Total neoadjuvant therapy (TNT)
- Volunteers
- 42 people
- Sponsor
- St. James's Hospital, Ireland
GLP - 1, Diabetes
FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP Support
In individuals with overweight/obesity, increases in physical activity (PA) can improve metabolic and cardiovascular health, independent of weight loss.
- Conditions
- GLP - 1, Diabetes, Obesity and Obesity-related Medical Conditions, Cardiovascular Diseases
- Trial name
- FIT-COACH (NCT06915090)
- Testing
- Health Coach/Fitbit
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
GLP-1 Concentration
Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1
Determine if consuming a high protein nutrition shake reduces gastrointestinal symptoms associated with semaglutide injections.
- Trial name
- NCT07096739
- Testing
- High protein shake
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kate Farms Inc
GLP-1, Nutrition
The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight
The aim of this study is to comprehensively assess the early and long-term effects of GLP-1 and GIP/GLP-1 analogue medications on metabolic and behavioral parameters, with particular emphasis on qualitative and quantitative…
- Trial name
- NCT07270497
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
GLP - 1, Bowel Preparation for Colonoscopy
The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies.
- Trial name
- NCT07127354
- Testing
- Continue GLP/GIP
- Where
- 3 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Weight Loss, Nutritional Deficiencies
Multivitamin Impact on Micronutrient Status in GLP-1 Users: A Randomized Trial
Rationale: Glucagon-Like Peptide-1 (GLP-1) receptor agonists have emerged as effective treatments for obesity and associated medical conditions.
- Conditions
- Weight Loss, Nutritional Deficiencies, GLP - 1, Obese Patients
- Trial name
- VITAGLP (NCT07234916)
- Testing
- Multivitamin Supplementation
- Where
- 2 sites in Netherlands
- Volunteers
- 246 people
- Sponsor
- Erasmus Medical Center
Adults, GLP-1
Impact of Probiotic (UltraFlora® Triplebiotic) on Weight Evolution on People After Discontinuation of GLP-1 Treatment.
This is a randomized, double-blind, double arm study involving 128 participants who will undergo a total participation period of 12 weeks.
- Trial name
- NCT07209046
- Testing
- UltraFlora® Triplebiotic
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Binge Eating Disorder Associated With Obesity, Binge Eating Disorder
Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity
This study is a clinical, longitudinal, non-randomized, prospective observational study that seeks to compare the treatment effects and safety of using GLP-1 analogues versus not using appetite suppressants during a lifestyle…
- Conditions
- Binge Eating Disorder Associated With Obesity, Binge Eating Disorder, Eating Disorder Binge, Eating Disorders
- Trial name
- BETTER-GLP1 (NCT07042672)
- Testing
- GLP-1, CBTe Group Therapy
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Blood Sugar; High, Overweight and Obesity
Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1
- Trial name
- RCT (NCT07141472)
- Testing
- GB
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Lawry Han
GLP-1, Adults
Impact of Multivitamin (PhytoMulti®) and a Probiotic (UltraFlora® Balance Probiotic) on Gut Health of People Taking GLP-1 Medication
This is a single-arm, open-label clinical trial involving 100 participants who will undergo a total participation period of 12 weeks.
- Trial name
- NCT07130396
- Testing
- Multivitamin and a Probiotic
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Longevity, GLP-1
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1…
- Conditions
- Longevity, GLP-1, Geroscience, Aging
- Trial name
- NCT07092618
- Testing
- Metformin, Rapamycin, Naltrexone
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- AgelessRx
Satiation, Satiety, Insulin
Plant-Based Meat Analogues and Human Health
The goal of this intervention trial is to compare the satiation effects induced by a single intake of vegan meat (VM) and genuine meat (GM) in twenty-five healthy participants, aged 25 to 50 years, from both genders.
- Conditions
- Satiation, Satiety, Insulin, Glucose, Leptin Levels
- Trial name
- VegAnimal (NCT07031752)
- Testing
- Postprandial Vegan Meat, Postprandial Meat
- Where
- Spain
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Universidad de Extremadura
IPMN, IPMN, Pancreatic
Impact of GLP-1 Receptor Agonists on Patients With IPMN
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy.
- Conditions
- IPMN, IPMN, Pancreatic, GLP-1, Intraductal Papillary Mucinous Neoplasm of Pancreas
- Trial name
- IPMN-GLP1RA (NCT07014709)
- Testing
- GLP1 receptor agonist
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Hôpital Fribourgeois
GLP-1, Gut Microbiota
Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1
Recently, it has been proposed that the consumption of non-nutritive sweeteners, including sucralose, it's not harmless and is related with metabolic effects.
- Conditions
- GLP-1, Gut Microbiota, Insulin Resistance
- Trial name
- NCT06094894
- Testing
- sucralose
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran